The researchers present their findings in a paper entitled “Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?” published in the Journal of Health Politics, Policy and Law on Jan. 5.
- Differential pharmaceutical patent lengths in the U.S. and in other jurisdictions such as the European Union. Currently, patent protection is 20 years from drug development, no matter how innovative the drug.
- Prohibiting the tax deduction of all drug marketing expenditures to reduce company incentives for developing and aggressively marketing weakly innovative drugs at the expense of more innovative drugs.
- Channeling pharmaceutical marketing tax resources into increased FDA oversight and Department of Justice enforcement of existing marketing regulations.
- Transparent disclosure of all drug company marketing expenditures to the public.
About the Belk College of Business
Accredited by AACSB International, the Belk College of Business at UNC Charlotte offers outstanding business education programs at the undergraduate, graduate, doctoral and executive levels.